Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ifosfamide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Chemotherapy + zoledronic acid | EXPERIMENTAL | - |
| chemotherapy | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| cisplatin | DRUG | - |
| doxorubicin hydrochloride | DRUG | - |
| etoposide | DRUG | - |
| ifosfamide | DRUG | - |
| methotrexate | DRUG | - |
| zoledronic acid | DRUG | - |
| conventional surgery | PROCEDURE | - |
Inclusion Criteria * Histologically confirmed high-grade osteosarcoma * Bilirubin ≤ 2 times upper limit of normal * No medical condition that would preclude study treatment * Not pregnant or nursing * Fertile patients must use effective contraception * Shortening fraction ≥ 28% * LVEF ≥ 50% * Glome...
Top 20 of 30 competitors
Ifosfamide is a small molecule oncology drug being studied for the treatment of sarcoma. It is currently in Phase 3 clinical development as part of a combined chemotherapy regimen. The drug is being evaluated in patients with osteosarcoma, a type of bone sarcoma, in a clinical trial conducted in France.
Ifosfamide is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting a Phase 3 clinical trial to evaluate the drug's efficacy in patients with sarcoma.
Ifosfamide is currently in Phase 3 clinical development for the treatment of sarcoma. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is active but not recruiting participants, with a planned enrollment of 318 patients.
Ifosfamide is being evaluated in a Phase 3 clinical trial registered as NCT00470223, titled 'Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma.' The trial is active but not recruiting, enrolls 318 patients with sarcoma, and is being conducted in France. The study includes patients aged 5 years and older.
Yes, ifosfamide is being tested in a randomized, active-controlled Phase 3 clinical trial. The study compares combined chemotherapy with or without zoledronic acid in patients with osteosarcoma. The trial is not double-blinded, and it uses a biomarker-selected patient population.